Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections
SARS-CoV-2-나이브 및 -경험 대상자에서 BNT162b2 mRNA 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성: 추가 용량 및 돌발 감염의 영향
Article
[키워드] administration
age
analyzed
Anti-nucleocapsid antibodies
anti-SARS-CoV-2
anti-spike antibodies
anti-spike antibody
antibodies
antibody
association
Belgium
benefit
blood sample
Blood samples
blood sampling
BNT162b2
BNT162b2 mRNA
BNT162b2 mRNA vaccine
booster
booster dose
booster doses
breakthrough infections
cell-mediated immune response
cellular
cellular and humoral immune response
Cellular immune response
cellular immune responses
collected
COVID-19
COVID-19 vaccine
DiaSorin
dose
Elecsy
enrolled
evaluated
greater
HCW
HCWs
Healthcare system
healthcare worker
Healthcare workers
help
Human
humoral
Humoral and cellular immune responses
humoral immune response
Humoral response
IFN-γ
IgG
immune protection
immune response
immune responses
immunization
immunogenicity
Impact
implication
increase in
individual level
individuals
Infection
initial
Kinetics
LIAISON
Lymphocytes
management
mandatory
mRNA vaccination
mRNA vaccine
naïve
naïve individuals
natural infection
Neutralization assay
neutralization capacity
Neutralizing antibodies
pandemic
participant
Participants
Peripheral blood
peripheral blood lymphocyte
peripheral blood lymphocytes
persistence
Prevent
Prospective Study
Qiagen
QuantiFERON
quantified
reduce
regimen
response
SARS- CoV-2
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 vaccination
second dose
secretion
severe COVID-19
significantly higher
tested
the SARS-CoV-2
triggering
understanding
university
vaccination
vaccine dose
variant
Vero E6
was performed
[DOI] 10.3389/fimmu.2022.863554 PMC 바로가기 [Article Type] Article
[DOI] 10.3389/fimmu.2022.863554 PMC 바로가기 [Article Type] Article